Search Results 251-260 of 18189 for peptides

  1. ... PEPTIDE ASSAY,183 301000116,HC C1 ESTERASE INHIB AG S,131 301000117,HC C1 ESTERASE INHIBITOR QUANT,132 301000118,HC CA URINE QUANT TIMED SPECIMEN,44 ...

  2. An Efficacy, Safety And Tolerability Study Of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections To Subjects With Heart Failure Due To Ischemic Dilated Cardiomyopathy (IDCM) - Mayo Clinic

    Have an N-terminal prohormone B-type natriuretic peptide (NT-proBNP) ≥2000 pg/mL or BNP ≥400 pg/mL within 30 days of screening (including screening); Have ...

  3. Radiology - Clinical trials

    ... peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous ...

  4. Acromegaly - Diagnosis and treatment - Mayo Clinic

    Unlike octreotide or lanreotide, which are peptides, paltusotine is not a peptide. ... peptide medicines. Somatostatins are the first line treatment for ...

  5. Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients - Mayo Clinic

    Deamidated gliadin peptide-IgA [DGP-IgA] (≥30 U; normal range: 0–20 U), but weak positive (20–30 U) is acceptable. Deamidated gliadin peptide-IgG [DGP ...

  6. Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors - Mayo Clinic

    ... peptide receptor radiotherapy (PRRT) and PRRT must be completed at least 8 weeks prior to registration; Radiological evidence for progressive disease ...

  7. Parkinson's test (a-Synuclein seed amplification assay) - Mayo Clinic

    The Parkinson's test is used by researchers during clinical trials. It's not available in a health care professional's office, but there's hope that it will be ...

  8. Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET - Mayo Clinic

    Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the study. Documented RECIST progression to previous treatments for the ...

  9. Publications - Paul M. Magtibay, M.D. - Mayo Clinic

    Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer. Sci Adv. 2025 Feb 21; 11 (8):eads7405 Epub 2025 Feb 19. View PubMed; Shah AS ...

  10. Mayo Clinic Transplant Center - Clinical trials

    The purpose of this study is to investigate ghrelin, a peptide that mechanistically carries the promise of therapeutics benefit for diverse aspects of morbidity ...